Showing 2631-2640 of 3569 results for "".
- App Launched for Medical Entrepreneurshttps://practicaldermatology.com/news/20120824-app_launched_for_medical_entrepreneurs/2459746/The free Medical Entrepreneur App went live on the Apple Store this month. The app, developed by Steven M. Hacker, MD, provides healthcare providers and medical students with business intelligence and decision making tools before, duri
- Nickel Reactions on the Rise. Diet to Blame?https://practicaldermatology.com/news/20120302-nickel_reactions_on_the_rise_diet_to_blame/2459857/Certain patients consuming healthy diets consisting of whole grains, legumes, nuts, and soy may be at increased risk of developing allergic reactions to nickel, according to dermatologist Matthew Zirwas, MD, an associate professor at
- The American Society for Laser Medicine and Surgery Names New Officershttps://practicaldermatology.com/news/the-american-society-for-laser-medicine-and-surgery-names-new-officers/2458185/The American Society for Laser Medicine and Surgery (ASLMS) introduced Mathew M. Avram, MD, JD, as its new President at the Annual Conference in April. Dr. Avram succeeds Kristen M. Kelly, MD, who now serves as the Society’s Past President. The 2017-18 ASLMS Executive Committee also i
- ODAC 2026 Adds Hands-On, High-Impact Workshopshttps://practicaldermatology.com/news/odac-2026-adds-hands-on-high-impact-workshops/2484689/The ODAC Dermatology Conference will return to Orlando, Florida, in 2026 with a refreshed slate of interactive, expert-led sessions that emphasize skill-building across medical, surgical, and aesthetic dermatology, organizers said in a press release. Scheduled for J
- Biologic Costs for Plaque Psoriasis Doubled Since 2007, Study Findshttps://practicaldermatology.com/news/biologic-costs-for-plaque-psoriasis-double-since-2007-study-finds/2474189/A new analysis shows the average net annual cost of first-line biologic treatments for plaque psoriasis more than doubled between 2007 and 2021, rising from $21,236 to $47,125. The study researchers, publishing online in J
- Humira Biosimilar Simlandi Now Available in the UShttps://practicaldermatology.com/news/humira-biosimilar-simlandi-now-available-us/2463126/Teva Pharmaceuticals and Alvotech announced the availability of Simlandi (adalimumab-ryvk) injection in the US as an interchangeable biosimilar to Humira. Simlandi is indicated for the treatment of adult plaque psoriasis and adult hidradenitis suppurativa, as well as adult rheumatoid arthritis, j
- Research IDs New Psoriasis Inflammation Pathwayhttps://practicaldermatology.com/news/research-ids-new-psoriasis-inflammation-pathway/2463125/Researchers from a recent study have identified a key biological pathway responsible for the inflammation seen in psoriasis, with potential implications for other inflammatory diseases like atopic dermatitis, allergic dermatitis, and hidradenitis suppurativa. The study, published in the j
- Partial Irreversible Electroporation May Help Extinguish Burn Scars Before They Starthttps://practicaldermatology.com/news/partial-irreversible-electroporation-may-help-extinguish-burn-scars-before-they-start/2458470/A new non-invasive method may help prevent burn scarring caused by the proliferation of collagen cells, report researchers from Tel Aviv University and Harvard University in the J
- Joseph C. Papa Assumes Role Of Chairman And Chief Executive Officer Of Valeanthttps://practicaldermatology.com/news/joseph-c-papa-assumes-role-of-chairman-and-chief-executive-officer-of-valeant/2458580/Joseph C. Papa has assumed the role of Chairman and Chief Executive Officer at Valeant Pharmaceuticals International, Inc. As previously announced, Joseph C. Papa succeeds J. Michael Pearson. &quo
- Ouchless Needle Announces First Exclusive International Distribution Agreement with Device Technologieshttps://practicaldermatology.com/news/20120501-ouchless_needle_announces_first_exclusive_international_distribution_agreement_with_device_technologies/2459811/Ouchless Needle by the BellaNovus Development Company announced their first international exclusive distribution agreement with Device Technologies for Australia and New Zealand. Developed by aesthetic plastic surgery innovator Marc J. Sa